Microwave Thermotherapy — CPB 0682 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0682 — its microwave thermotherapy coverage policy — effective October 17, 2025. Every indication listed in this policy is experimental, investigational, or unproven. If your billing team submits claims for microwave thermotherapy against any of the 21+ indications listed, expect denial.

This update to CPB 0682 Aetna's microwave thermotherapy policy codifies non-coverage across a wide range of oncologic and non-oncologic indications. HCPCS code C9751 (bronchoscopic microwave ablation) is explicitly listed as not covered for the indications in this policy. CPT codes 77280–77295 appear as related radiation therapy codes. If you bill for any microwave-based thermal treatment in these clinical contexts, this policy directly affects your reimbursement.

Quick-Reference Table

Aetna Microwave Thermotherapy Coverage Criteria and Medical Necessity Requirements 2025

Here is the short version of this policy: Aetna does not cover microwave thermotherapy for any of the indications listed in CPB 0682. The policy does not establish medical necessity criteria to meet — it classifies this entire treatment category as experimental, investigational, or unproven.

This is important for your billing team to understand. The absence of coverage criteria is itself the policy. There is no documentation checklist, no clinical threshold, and no prior authorization pathway that will unlock coverage for these indications. Claims submitted with medical necessity arguments will still deny.

The real issue is scope. CPB 0682 spans 21 named indications — from bladder cancer and breast cancer to rheumatoid arthritis, chronic pelvic pain syndrome, keratoconus, and cutaneous verrucae (warts). This is not a narrow carve-out. It is a blanket non-coverage statement across a wide clinical footprint.

Aetna's rationale is consistent throughout the policy: insufficient evidence of effectiveness. That language matters for appeals. Aetna's rationale cites insufficient evidence of effectiveness — any appeal strategy should account for that evidentiary standard.

Two variant treatment approaches also get explicit non-coverage designations. Microwave thermotherapy enhanced with hybrid magnetic nanoparticles is not covered for liver cancer. Microwave thermotherapy combined with TIPE2 (tumor necrosis factor-alpha induced protein-8-like 2) is not covered for colon cancer. Both are experimental per the updated policy. If your oncology billing team is tracking novel combination therapies, flag these specifically.

For microwave thermotherapy for benign prostatic hypertrophy (BPH), this policy does not apply. Aetna handles BPH separately under CPB 0079. Similarly, ablation of hepatic lesions falls under CPB 0274. If your team bills for either of those, review those policies independently. Confusing CPB 0682 with BPH-related billing is a common mismatch — don't assume the same non-coverage logic from this policy applies there.

Aetna Microwave Thermotherapy Exclusions and Non-Covered Indications

The full list of indications Aetna considers experimental, investigational, or unproven under CPB 0682:

This is not an all-inclusive list — the policy explicitly states that. If a provider is using microwave thermotherapy for an indication not listed here, don't assume it's covered. Assume it requires verification before you submit.

The combination-therapy exclusions deserve special attention. Microwave thermotherapy enhanced with hybrid magnetic nanoparticles for liver cancer and microwave thermotherapy combined with TIPE2 for colon cancer each get their own experimental designation. These aren't just variations of the same treatment — Aetna evaluated them separately and reached the same conclusion. Your billing guidelines should flag any claim combining these approaches.

Coverage Indications at a Glance

Aetna Microwave Thermotherapy Billing Guidelines and Action Items 2025

The effective date of October 17, 2025 is the hard line here. Take these steps before that date.

If your patient mix includes a high volume of any of the listed indications — particularly lung, breast, or pancreatic cancer patients being evaluated for thermal ablation — talk to your compliance officer before October 17, 2025. The financial exposure across those oncology service lines can add up fast.

CPT, HCPCS, and ICD-10 Codes for Microwave Thermotherapy Under CPB 0682

Not Covered HCPCS Codes

Key ICD-10-CM Diagnosis Codes

The full policy lists 215 ICD-10-CM codes. The ranges above capture the primary diagnostic groupings. Review the full code set at the source policy before finalizing your charge capture updates.